Prognostic significance of measurable residual disease based on multiparameter flow cytometry in childhood acute myeloid leukemia.
10.7499/j.issn.1008-8830.2106102
- Author:
Ya HUO
1
;
Xian-Min GUAN
1
;
Ying DOU
1
;
Xian-Hao WEN
1
;
Yu-Xia GUO
1
;
Ya-Li SHEN
1
;
Xi-Zhou AN
1
;
Jie YU
1
Author Information
1. Department of Hematology and Oncology, Children's Hospital Affiliated to Chongqing Medical University/Ministry of Education Key Laboratory of Child Development and Disorders/National Children's Health and Disease Clinical Medicine Research Center/National International Science and Technology Cooperation Base for Critical Child Developmental Diseases/Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China (Yu J, Email: 1808106657@qq. com).
- Publication Type:Journal Article
- Keywords:
2015-AML-03 regimen;
Acute myeloid leukemia;
Child;
Measurable residual disease;
Multiparameter flow cytometry
- MeSH:
Child;
Disease Progression;
Flow Cytometry;
Humans;
Leukemia, Myeloid, Acute/drug therapy*;
Neoplasm, Residual;
Prognosis
- From:
Chinese Journal of Contemporary Pediatrics
2021;23(11):1111-1118
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:To study the prognostic value of measurable residual disease (MRD) for childhood acute myeloid leukemia (AML) by analyzing MRD-guided risk stratification therapy.
METHODS:A total of 93 children with AML were prospectively enrolled in this study. Chemotherapy with the 2015-AML-03 regimen was completed according to the risk stratification determined by genetic abnormality at initial diagnosis and MRD and bone marrow cytology after induction therapy I. Multiparameter flow cytometry was used to dynamically monitor MRD and analyze the prognostic effect of MRD on 3-year cumulative incidence of recurrence (CIR) rate, event-free survival (EFS) rate, and overall survival (OS) rate.
RESULTS:The 93 children with AML had a 3-year CIR rate of 48%±6%, a median time to recurrence of 11 months (range 2-32 months), a 3-year OS rate of 65%±6%, and a 3-year EFS rate of 50%±5%. After induction therapy I and intensive therapy I, the MRD-positive children had a significantly higher 3-year CIR rate and significantly lower 3-year EFS and OS rates than the MRD-negative children (
CONCLUSIONS:MRD has predictive value for the prognosis of children with AML. Based on the MRD-guided risk stratification therapy, reasonable application of chemotherapy may improve the overall prognosis of children with AML.
